近日,一则重磅消息在医药行业引发轩然大波。 强生 旗下子公司因在HIV药物营销推广过程中存在违规操作,被联邦法官判罚16.4亿美元。这一事件不仅对强生公司自身造成巨大冲击,也为整个医药行业的合规发展敲响了警钟。该案件源于举报人发起的诉讼。美国新泽西州特伦顿地区的法官Zahid Quraishi经审理后裁定,强生子公司杨森(Janssen)在推广HIV药物Prezista和Intelence时,存在...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.